2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrido[3,4-d]pyrimidin-4-amine | 1220517-86-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrido[3,4-d]pyrimidin-4-amine
• 英文别名: 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrido[2,3-d]pyrimidin-4-amine；2-chloro-N-(1-methylimidazol-4-yl)pyrido[2,3-d]pyrimidin-4-amine
• CAS: 1220517-86-1
• 化学式: C₁₁H₉ClN₆
• 分子量: 260.686
• InChiKey: XPWQQEFPSOCIJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-1-(5-氟嘧啶-2-基)乙胺盐酸盐 、 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrido[3,4-d]pyrimidin-4-amine 、 三氟乙酸 在 N,N-二异丙基乙胺 作用下， 以 正丁醇 、 水 、 乙腈 为溶剂， 反应 6.0h， 以28%的产率得到N²-[1-(5-fluoropyrimidin-2-yl)ethyl]-N⁴-(1-methyl-1H-imidazol-4-yl)pyrido[3,4-d]pyrimidine-2,4-diamine trifluoroacetate salt
  参考文献：
  名称：

  Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors

  摘要：

  Structure based design, synthesis, and biological evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described. Using the C-ring fragment from our first clinical candidate AZD1480 (24), optimization of the series led to the discovery of compound 19a, a potent, orally bioavailable Jak2 inhibitor. Compound 19a displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells. Compound 19a demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.

  DOI：

  10.1021/jm401546n
• 作为产物：
  描述：

  吡啶并[2,3-D]嘧啶-2,4(1H,3H)-二酮 在 N,N-二甲基苯胺 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 乙腈 为溶剂， 反应 4.0h， 生成 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrido[3,4-d]pyrimidin-4-amine
  参考文献：
  名称：

  Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors

  摘要：

  Structure based design, synthesis, and biological evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described. Using the C-ring fragment from our first clinical candidate AZD1480 (24), optimization of the series led to the discovery of compound 19a, a potent, orally bioavailable Jak2 inhibitor. Compound 19a displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells. Compound 19a demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.

  DOI：

  10.1021/jm401546n

文献信息

• [EN] HETEROCYCLIC JAK KINASE INHIBITORS<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE LA KINASE JAK
  申请人：ASTRAZENECA AB

  公开号：WO2010038060A1

  公开（公告）日：2010-04-08

  The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.

  本发明涉及式（I）化合物及其盐、药物组合物、使用方法和制备方法。这些化合物可用于治疗骨髓增生性疾病和癌症。
• HETEROCYCLIC JAK KINASE INHIBITORS
  申请人：Chuaqui Claudio Edmundo

  公开号：US20110201628A1

  公开（公告）日：2011-08-18

  The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.

  本发明涉及公式（I）的化合物及其盐，制药组合物，使用方法和制备方法。这些化合物提供了治疗骨髓增生性疾病和癌症的方法。
• Discovery of 1-Methyl-1<i>H</i>-imidazole Derivatives as Potent Jak2 Inhibitors
  作者：Qibin Su、Stephanos Ioannidis、Claudio Chuaqui、Lynsie Almeida、Marat Alimzhanov、Geraldine Bebernitz、Kirsten Bell、Michael Block、Tina Howard、Shan Huang、Dennis Huszar、Jon A. Read、Caroline Rivard Costa、Jie Shi、Mei Su、Minwei Ye、Michael Zinda

  DOI：10.1021/jm401546n

  日期：2014.1.9

  Structure based design, synthesis, and biological evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described. Using the C-ring fragment from our first clinical candidate AZD1480 (24), optimization of the series led to the discovery of compound 19a, a potent, orally bioavailable Jak2 inhibitor. Compound 19a displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells. Compound 19a demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.